Nature Communications (Mar 2023)
Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
- Anna R. Mäkelä,
- Hasan Uğurlu,
- Liina Hannula,
- Ravi Kant,
- Petja Salminen,
- Riku Fagerlund,
- Sanna Mäki,
- Anu Haveri,
- Tomas Strandin,
- Lauri Kareinen,
- Jussi Hepojoki,
- Suvi Kuivanen,
- Lev Levanov,
- Arja Pasternack,
- Rauno A. Naves,
- Olli Ritvos,
- Pamela Österlund,
- Tarja Sironen,
- Olli Vapalahti,
- Anja Kipar,
- Juha T. Huiskonen,
- Ilona Rissanen,
- Kalle Saksela
Affiliations
- Anna R. Mäkelä
- Department of Virology, University of Helsinki
- Hasan Uğurlu
- Department of Virology, University of Helsinki
- Liina Hannula
- Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki
- Ravi Kant
- Department of Virology, University of Helsinki
- Petja Salminen
- Department of Virology, University of Helsinki
- Riku Fagerlund
- Department of Virology, University of Helsinki
- Sanna Mäki
- Department of Virology, University of Helsinki
- Anu Haveri
- Finnish Institute for Health and Welfare
- Tomas Strandin
- Department of Virology, University of Helsinki
- Lauri Kareinen
- Department of Virology, University of Helsinki
- Jussi Hepojoki
- Department of Virology, University of Helsinki
- Suvi Kuivanen
- Department of Virology, University of Helsinki
- Lev Levanov
- Department of Virology, University of Helsinki
- Arja Pasternack
- Department of Physiology, University of Helsinki
- Rauno A. Naves
- Department of Physiology, University of Helsinki
- Olli Ritvos
- Department of Physiology, University of Helsinki
- Pamela Österlund
- Finnish Institute for Health and Welfare
- Tarja Sironen
- Department of Virology, University of Helsinki
- Olli Vapalahti
- Department of Virology, University of Helsinki
- Anja Kipar
- Department of Basic Veterinary Sciences, University of Helsinki
- Juha T. Huiskonen
- Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki
- Ilona Rissanen
- Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki
- Kalle Saksela
- Department of Virology, University of Helsinki
- DOI
- https://doi.org/10.1038/s41467-023-37290-6
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 12
Abstract
Here the authors describe a small antibody-like protein that can prevent infection by diverse SARS-CoV-2 variants in cell culture and in mice that were intranasally treated with this inhibitor before or shortly after being exposed to the virus.
